Skip to main content

Can you take Revuforj with Tacrolimus topical?

1 drug interaction and 11 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

tacrolimus topical revumenib

Applies to: tacrolimus topical and Revuforj (revumenib)

Some of the medication in tacrolimus topical may be absorbed into the bloodstream following local application. Although serious side effects are not very common with topically applied preparations because only limited amounts of the medication generally get absorbed into the bloodstream from the skin they can sometimes occur, for example, when combined with other medications that have similar side effects.

Using tacrolimus topical together with revumenib may have additive effects on the immune system. This may increase the risk of serious side effects such as reduced immune function, and increased risk of infections.

Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need more frequent monitoring by your doctor to safely use both medications.

It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

revumenib Food/Lifestyle

Applies to: Revuforj (revumenib)

High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).

Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.

You may be more susceptible if you have:

  • a heart condition called congenital long QT syndrome
  • other cardiac diseases
  • conduction abnormalities
  • electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)

Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.

Symptoms of differentiation syndrome include:

  • fever
  • cough
  • shortness of breath
  • severe headache
  • confusion
  • dizziness
  • rapid weight gain
  • swelling
  • decreased urination

You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.

The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.

Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Disease interactions

10 potential interactions Applies to: 9 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Liver Disease, and Long QT Syndrome.

Arrhythmia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Heart Failure

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Heart Failure.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Hypokalemia

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Immunodeficiency

Major:

tacrolimus topical

Tacrolimus topical has a major potential interaction with Immunodeficiency.

The use of calcineurin inhibitors as pimecrolimus and tacrolimus topical should be avoided in immunocompromised adults and children, including patients on systemic immunosuppressive medications. Although causal relationship has not been established, there is a concern about a potential risk of infections, lymphomas and skin malignancies when using topical calcineurin inhibitors for a prolonged time.

Liver Disease

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Liver Disease.

Revumenib has not been studied in patients with severe liver or renal impairment.

Long QT Syndrome

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Magnesium Imbalance

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.

Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.

Renal Dysfunction

Moderate:

Revuforj

The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.

Revumenib has not been studied in patients with severe liver or renal impairment.

Moderate:

tacrolimus topical

Tacrolimus topical has a moderate potential interaction with Renal Dysfunction.

Rare postmarketing cases of acute renal failure have been reported in patients treated with topical tacrolimus. Systemic absorption is most likely to occur in patients with epidermal barrier defects, and when topical tacrolimus is applied to large body surface areas. Caution should be exercised in patients with history of renal impairment or predisposed to renal impairment.

Skin Cancer

Moderate:

tacrolimus topical

Tacrolimus topical has a moderate potential interaction with Skin Cancer.

The use of calcineurin inhibitors such as pimecrolimus and tacrolimus topical should be avoided on malignant or premalignant skin conditions. Some of these conditions might present as dermatitis. Calcineurin inhibitors should also be avoided in any skin conditions where there is the potential for increased systemic absorption of the medication as when there is a skin barrier defect.

Report options

Loading...
QR code containing a link to this page

More resources

Revuforj

A total of 583 drugs are known to interact with Revuforj.

tacrolimus topical

A total of 409 drugs are known to interact with tacrolimus topical.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer